Neumora Therapeutics (NASDAQ:NMRA) Given New $7.00 Price Target at HC Wainwright

Neumora Therapeutics (NASDAQ:NMRA) had its price objective lowered by equities researchers at HC Wainwright from $18.00 to $7.00 in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the stock.

NMRA has been the subject of a number of other reports. Needham & Company LLC lowered their price objective on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Tuesday, April 21st. Guggenheim reissued a “buy” rating and set a $14.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. Finally, William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Neumora Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $7.14.

Neumora Therapeutics Stock Performance

Shares of Neumora Therapeutics stock opened at $0.91 on Tuesday. Neumora Therapeutics has a one year low of $0.72 and a one year high of $3.65. The company has a market cap of $169.44 million, a PE ratio of -0.69 and a beta of 2.74. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.09 and a current ratio of 5.09. The business has a 50-day simple moving average of $1.95 and a 200-day simple moving average of $2.24.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. On average, equities research analysts forecast that Neumora Therapeutics will post -0.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Several large investors have recently modified their holdings of the company. Siren L.L.C. boosted its holdings in shares of Neumora Therapeutics by 35.1% in the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after acquiring an additional 2,209,039 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Neumora Therapeutics in the first quarter valued at approximately $9,953,000. Millennium Management LLC boosted its holdings in shares of Neumora Therapeutics by 80.1% in the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after acquiring an additional 1,608,266 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Neumora Therapeutics by 24.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock valued at $2,588,000 after acquiring an additional 281,926 shares during the period. Finally, Ikarian Capital LLC boosted its holdings in shares of Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after acquiring an additional 1,265,910 shares during the period. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics News Roundup

Here are the key news stories impacting Neumora Therapeutics this week:

• Negative Sentiment: Neumora said navacaprant failed to show statistically significant benefit in two Phase 3 depression trials, leading it to end development of the drug. Article Title
• Negative Sentiment: The company plans to lay off about 35% of staff as it restructures following the trial failures, signaling cost-cutting and reduced confidence in the lead program. Article Title
• Negative Sentiment: Several outlets reported the stock was on track for a severe drop after the Phase 3 failures, and a shareholder law firm announced an investigation into potential securities-law issues. Article Title
• Neutral Sentiment: Neumora said it still expects a cash runway into the third quarter of 2027 and will focus on other pipeline assets, including NMRA-511, NMRA-898 and NMRA-215. Article Title

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.